1.
Bioorg Med Chem Lett
; 14(2): 351-5, 2004 Jan 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14698157
RESUMO
Modifications to the basic side-chain of early lead structures of the indolyl quinolinone class of KDR kinase inhibitors resulted in improved pharmacokinetic and ancillary profiles. Specifically, compounds bearing 5-amido- and 5-sulphonamido-indolyl substituents exhibited lower plasma clearance and weaker binding affinity for the I(Kr) potassium channel hERG.